Eunchong Park is a Senior Scientist at AstraZeneca, specializing in Early Respiratory & Immunology. They are self-driven and investigate CD4+ T cell pathogenicity in autoimmune diseases, focusing on identifying and validating drug targets as well as developing therapies such as CAR-Treg cell therapy in collaboration with Quell Therapeutics. Eunchong earned a PhD in Immunology from Duke University, where their research revealed important roles of various proteins in Th17 cell behavior related to autoimmune conditions. Additionally, they have collaborated on developing antifungal drugs and conducted undergraduate research on dendritic cell activation at Korea University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices